TITLE

Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes

AUTHOR(S)
Pantani, Lucia; Zamagni, Elena; Zannetti, Beatrice; Pezzi, Annalisa; Tacchetti, Paola; Brioli, Annamaria; Mancuso, Katia; Perrone, Giulia; Rocchi, Serena; Tosi, Patrizia; Cavo, Michele
PUB. DATE
January 2014
SOURCE
Annals of Hematology;Jan2014, Vol. 93 Issue 1, p123
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM). This retrospective study investigated the combination of bort (1.3 mg/m on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy. The median number of prior lines of therapy was 2. Eighty-seven percent of the patients had received immunomodulatory drugs included in some line of therapy before bort-dex. The median number of bort-dex cycles was 6, up to a maximum of 12 cycles. On an intention-to-treat basis, 55 % of the patients achieved at least partial response, including 19 % CR and 35 % achieved at least very good partial response. Median durations of response, time to next therapy and treatment-free interval were 8, 11.2, and 5.1 months, respectively. The most relevant adverse event was peripheral neuropathy, which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %. With a median follow up of 22 months, median time to progression, progression-free survival (PFS) and overall survival (OS) were 8.9, 8.7, and 22 months, respectively. Prolonged PFS and OS were observed in patients achieving CR and receiving bort-dex a single line of prior therapy. Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
ACCESSION #
93391781

 

Related Articles

  • The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation-a single institutional experience in Taiwan. Huang, Tzu-Chuan; Chen, Jia-Hong; Wu, Yi-Ying; Chang, Ping-Ying; Dai, Ming-Shen; Chao, Tsu-Yi; Kao, Woei-Yau; Chen, Yeu-Chin; Ho, Ching-Liang // Annals of Hematology;Jan2015, Vol. 94 Issue 1, p107 

    Multiple myeloma (MM) is characterized by the neoplastic proliferation of monoclonal plasma cells in the bone marrow and results in complications. In Taiwan, melphalan and several novel agents are used to treat myeloma patients who are not candidate for hematopoietic stem cell transplant (HSCT)....

  • Combination regimen extended PFS in multiple myeloma. Adams, Stacey; Southall, Jennifer; Todak, Alexandra // Hem/Onc Today;7/25/2014, Vol. 15 Issue 14, p25 

    The article discusses a randomized, double blind and placebo-controlled phase three trial which concluded that addition of panobinostat to bortezomib and dexamethasone extends progression-free survival (PFS) in patients with relapsed or relapsed and refractory multiple myeloma.

  • Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. Duru, Adil Doganay; Sutlu, Tolga; Wallblom, Ann; Uttervall, Katarina; Lund, Johan; Stellan, Birgitta; Gahrton, Gösta; Nahi, Hareth; Alici, Evren // PLoS ONE;9/17/2015, Vol. 10 Issue 9, p1 

    Loss of the chromosomal region 8p21 negatively effects survival in patients with multiple myeloma (MM) that undergo autologous stem cell transplantation (ASCT). In this study, we aimed to identify the immunological and molecular consequences of del(8)(p21) with regards to treatment response and...

  • Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. Poenisch, Wolfram; Plötze, Madlen; Holzvogt, Bruno; Andrea, Marc; Schliwa, Thomas; Zehrfeld, Thomas; Hammerschmidt, Doreen; Schwarz, Maik; Edelmann, Thomas; Becker, Cornelia; Hoffmann, Franz; Schwarzer, Andreas; Kreibich, Ute; Gutsche, Kerstin; Reifenrath, Kolja; Schwarzbach, Heidrun; Heyn, Simone; Franke, Georg-Nikolaus; Jentzsch, Madlen; Leiblein, Sabine // Journal of Cancer Research & Clinical Oncology;Nov2015, Vol. 141 Issue 11, p2013 

    Introduction: Reliable information on stem cell toxicity and mobilization of stem cells for autologous stem cell transplantation (SCT) after induction treatment with a combination of bendamustine, prednisone and bortezomib (BPV) is missing. Materials and methods: A retrospective analysis of...

  • Therapeutic advancements in multiple myeloma. Gozzetti, Alessandro; Candi, Veronica; Papini, Giulia; Bocchia, Monica // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Multiplemyeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission...

  • Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma. Cerchione, Claudio; Nappi, Davide; Di Perna, Maria; Zacheo, Irene; Pareto, Anna Emanuele; Picardi, Marco; Catalano, Lucio; Pane, Fabrizio // Case Reports in Hematology;10/27/2016, p1 

    The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of available therapies becomes very poor, and the...

  • A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma. Ibata, Soushi; Sato, Tsutomu; Kuroda, Hiroyuki; Nagamachi, Yasuhiro; Iyama, Satoshi; Fujimi, Akihito; Kamihara, Yusuke; Konuma, Yuichi; Yoshida, Masahiro; Tatekoshi, Ayumi; Hashimoto, Akari; Horiguchi, Hiroto; Ono, Kaoru; Murase, Kazuyuki; Takada, Kohichi; Miyanishi, Koji; Kobune, Masayoshi; Hirayama, Yasuo; Kato, Junji // Cancer Chemotherapy & Pharmacology;Nov2016, Vol. 78 Issue 5, p1041 

    Purpose: Consolidation/maintenance therapy induces deep remission in patients with multiple myeloma (MM); however, the most suitable regimen has been under investigation. The combination therapy with bortezomib, lenalidomide and dexamethasone (VRD) is a powerful regimen for...

  • A long-term favorable response and effective control of neutropenia obtained by low-dose pomalidomide treatment in a patient with relapsed refractory multiple myeloma: a case report. Yasunobu Sekiguchi; Tadaaki Inano; Yasutaka Fukuda; Haruko Takizawa; Mutsumi Wakabayashi; Keiji Sugimoto; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 11, p22561 

    In June 2011, a 66-year-old woman was diagnosed as multiple myeloma (IgG-k type). In July 2011, she received bortezomib and dexamethasone therapy with a 5-week cycle. After the third treatment cycle, the patient showed disease progression to secondary plasma cell leukemia. In September 2011,...

  • Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Gimsing, P; Hjertner, Ø; Abildgaard, N; Andersen, N F; Dahl, T G; Gregersen, H; Klausen, T W; Mellqvist, U-H; Linder, O; Lindås, R; Tøffner Clausen, N; Lenhoff, S // Bone Marrow Transplantation;Oct2015, Vol. 50 Issue 10, p1306 

    Until recently, only retrospective studies had been published on salvage high-dose melphalan (HDM) with autologous stem cell 'transplantation' (ASCT). In a prospective, nonrandomized phase-2 study, we treated 53 bortezomib-naïve patients with bortezomib-dexamethasone as induction and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics